Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR(TM) in Combination with Checkpoint Inhibitor

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Analysts Hunt for Undervalued Biotech Stocks
Bloodstream Infections - From Threats to Solutions
Biopharma Stocks Transformative Innovation for the Future of Health
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
Sidoti Events, LLC's Virtual June Small-Cap Conference
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.